Syros Pharmaceuticals (SYRS) Upgraded at Zacks Investment Research

Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday. The brokerage presently has a $11.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 9.45% from the company’s previous close.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Several other equities research analysts have also recently weighed in on the company. Roth Capital started coverage on Syros Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price objective for the company. Piper Jaffray Companies reissued an “overweight” rating and issued a $30.00 price objective on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st. ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Oppenheimer reissued a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, December 7th. Finally, Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $22.23.

Syros Pharmaceuticals (SYRS) traded up $0.51 on Friday, hitting $10.05. The stock had a trading volume of 285,800 shares, compared to its average volume of 236,333. Syros Pharmaceuticals has a 12 month low of $6.30 and a 12 month high of $24.38. The company has a market capitalization of $264.28 and a PE ratio of -5.78.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). analysts predict that Syros Pharmaceuticals will post -2.12 EPS for the current fiscal year.

In other news, Director Srinivas Akkaraju bought 109,774 shares of Syros Pharmaceuticals stock in a transaction that occurred on Thursday, December 14th. The stock was purchased at an average cost of $9.03 per share, with a total value of $991,259.22. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeremy P. Springhorn bought 15,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average cost of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System lifted its position in Syros Pharmaceuticals by 131.3% in the second quarter. California State Teachers Retirement System now owns 22,200 shares of the company’s stock worth $357,000 after purchasing an additional 12,600 shares during the period. Bank of New York Mellon Corp lifted its position in Syros Pharmaceuticals by 157.9% in the second quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock worth $483,000 after purchasing an additional 18,382 shares during the period. Citadel Advisors LLC bought a new position in Syros Pharmaceuticals in the third quarter worth $975,000. Ark Investment Management LLC raised its stake in Syros Pharmaceuticals by 114.7% during the second quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock worth $285,000 after acquiring an additional 9,460 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Syros Pharmaceuticals by 189.6% during the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock worth $6,156,000 after acquiring an additional 250,507 shares in the last quarter. 57.96% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Syros Pharmaceuticals (SYRS) Upgraded at Zacks Investment Research” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/05/syros-pharmaceuticals-syrs-upgraded-at-zacks-investment-research.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply